Radiopharmaceuticals for Oncology, Nonspecific to Glucose (PET and SPECT)

Abstract

To date, the most common drug for the diagnosis of cancer tumors is [18F]-fluorodeoxyglucose, an radiopharmaceuticals for positron emission tomography diagnostics using the fact of increased glucose metabolism by cancer cells. At the same time, there are a number of cases where an approach based on glucose derivatives is not applicable. In many cases, inflammation or other benign processes are indistinguishable from tumor formations. For such cases of non-specificity of oncologies to glucose (not only tumor cells, but also healthy cells actively consume [18F]-fluorodeoxyglucose), the use of other metabolic pathways is required, which, in the case of a specific tumor in this organ, will be specific to the radiopharmaceuticals used.